NASDAQ:EIDX - Eidos Therapeutics Stock Price, News, & Analysis

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

Eidos Therapeutics Inc (NASDAQ:EIDX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.32) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.32). View Eidos Therapeutics' Earnings History.

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Eidos Therapeutics.

7 analysts have issued 12-month price targets for Eidos Therapeutics' shares. Their forecasts range from $13.00 to $40.00. On average, they expect Eidos Therapeutics' stock price to reach $30.2857 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price. View Analyst Price Targets for Eidos Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Media coverage about EIDX stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eidos Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Eidos Therapeutics.

Eidos Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totalling 3,213,200 shares, an increase of 19.6% from the April 30th total of 2,685,800 shares. Based on an average daily volume of 150,100 shares, the days-to-cover ratio is currently 21.4 days. Approximately 37.3% of the company's shares are short sold. View Eidos Therapeutics' Current Options Chain.

Some companies that are related to Eidos Therapeutics include Blueprint Medicines (BPMC), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Agios Pharmaceuticals (AGIO), Uniqure (QURE), Arena Pharmaceuticals (ARNA) and Amicus Therapeutics (FOLD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), Micron Technology (MU), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Roku (ROKU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), bluebird bio (BLUE), Celgene (CELG) and DexCom (DXCM).

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

Eidos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (2.31%), Candriam Luxembourg S.C.A. (1.15%), American International Group Inc. (0.67%), Victory Capital Management Inc. (0.50%), Fiera Capital Corp (0.25%) and Rhumbline Advisers (0.05%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Jonathan C Fox, Neil Kumar, Rajeev M Shah and Uma Sinha. View Institutional Ownership Trends for Eidos Therapeutics.

EIDX stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Victory Capital Management Inc., Oppenheimer Asset Management Inc. and Redmile Group LLC. Company insiders that have sold Eidos Therapeutics company stock in the last year include Bridgebio Pharma Llc, Cameron Turtle, Christine Siu, Jonathan C Fox and Uma Sinha. View Insider Buying and Selling for Eidos Therapeutics.

EIDX stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Rhumbline Advisers, Fiduciary Trust Co., MetLife Investment Advisors LLC, Metropolitan Life Insurance Co NY, American International Group Inc. and BNP Paribas Arbitrage SA. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EIDX stock can currently be purchased for approximately $28.97.

Eidos Therapeutics has a market capitalization of $1.07 billion. The company earns $-33,290,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.View Additional Information About Eidos Therapeutics.

The official website for Eidos Therapeutics is http://www.eidostx.com/.

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]